AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 FEB 6 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - A group studying hepatitis C virus DNA vaccines has found granulocyte macrophage-colony stimulating factor (GM-CSF) gene therapy increases their effectiveness in inoculated mice.
The group, lead by P. Ou-Yang, works in the College of Medicine at National Taiwan University of Taipei. According to their data, immune response was heightened in mice immunized with both agents.
"In this study, female Balb/c mice immunized with HCV core plasmid DNA with or without adjuvant GM-CSF cytokine gene could induce both cellular immune response and HCV core-specific antibody titers after injection," Ou-Yang and colleagues said.
More analysis revealed that in mice given both the DNA vaccine and the gene therapy, antibody titer, as well as cytotoxic T-cell activity, was greater.
Investigators believed the local lymph nodes of the inoculated mice played a key role in immune response activity because reporter protein, expressed after animals were treated with specially designed constructs containing reporter gene and cytokine gene plasmid, could be detected within inguinal nodes within a day of gene therapy administration, "especially in mice immunized with HCV/core plasmid plus ...